期刊文献+

Ki-67在卵巢癌中的表达差异及卵巢癌高危因素的研究 被引量:2

Difference in Ki-67 Expression among Different Ovarian Carcinomas and Their High Risk Factors
下载PDF
导出
摘要 目的通过分析恶性卵巢癌之间Ki-67表达的差异和高危因素的研究,探讨其临床应用价值。方法 156例卵巢癌患者,按病理FIGO(2000年)分期法分类:浆液性乳头状癌81例,黏液性乳头状癌26例,子宫内膜样癌16例,透明细胞癌8例,恶性畸胎瘤5例,颗粒细胞瘤12例,未分化癌3例,无性细胞瘤5例。通过Cox模型筛选法,参数评估生存率的危险因素,并通过免疫组织化学法分析不同分期卵巢癌病例Ki-67表达的不同情况。结果化疗次数和孕次是保护因素(b=-0.175,RR=0.840;b=-0.189,RR=0.828);局部淋巴结转移、远处转移和盆腔浸润是危险因素(b=0.638,RR=1.893;b=1.929,RR=6.886;b=0.971,RR=2.640)。156例患者中85例患者进行Ki-67的免疫组织化学检测,其中18例患者Ki-67表达呈阴性(0级),21例患者Ki-67表达呈弱阳性(Ⅰ级),20例患者Ki-67表达呈强阳性(Ⅱ级),26例患者表达呈强阳性(Ⅲ级)。有无侵润及不同病理组织分类中Ki-67表达水平比较差异有统计学意义(P<0.05或P<0.01)。结论卵巢癌化疗次数和孕次是保护因素,而局部淋巴结转移、远处转移和盆腔浸润是危险因素。 Objective To investigate the clinical value of Ki-67 through analyzing the difference in Ki-67 expression among different ovarian carcinomas and their high risk factors. Methods According to the International Federation of Gynecology and Obstetrics(FIGO 2000) staging, 156 ovarian cancer patients were grouped as follows: serous papillary carcinoma(n=81), papillary mucinous carcinoma(n=26), endometrioid carcinoma(n=16), clear cell carcinoma(n=8), malignant teratoma(n=5), granulosa cell tumor(n=12), undifferentiated carcinoma(n=3), and dysgerminoma(n=5). Cox model screening method was used to parametrically estimate the risk factors for survival rate and immunohistochemistry was used to analyze the Ki-67 expression in different stages of ovarian cancer. Results The protective factors included the number of chemotherapy(b=-0.175, RR=0.840) and number of pregnancy(b=-0.189, RR=0.828). The risk factors included regional lymph node metastasis(b=0.638, RR=1.893), distant metastasis(b=1.929,RR=6.886) and pelvic infiltration(b=0.971, RR=2.640). The expression of Ki-67 was assessed in 85 of the 156 patients. Among them, immunohistochemistry showed negative staining(grade 0) in 18,weakly positive staining(gradeⅠ) in 21, strongly positive staining(gradeⅡ) in 20, and ultra-strongly positive staining(grade Ⅲ) in 26.There were significant differences in the expression of Ki-67 were found among different pathological classification, as well as among different with or with out invasion types of ovarian cancer(P〈0.05 or P〈0.01). Conclusion The number of chemotherapy and number of pregnancy are the protective factors for ovarian cancer, whereas regional lymph node metastasis, distant metastasis and pelvic infiltration are the risk factors for ovarian cancer.
出处 《实用临床医学(江西)》 CAS 2014年第10期62-65,70,共5页 Practical Clinical Medicine
关键词 KI-67 卵巢癌 免疫组织化学 Ki-67 ovarian cancer immunohistochemistry
  • 相关文献

参考文献18

  • 1Burger R A,Brady M F, Bookman M A,et al.Incorporation of bevacizumab in the primary treatment of ovarian can- cer[J ].N Engl J Med,2011,365(26):2473-2483.
  • 2Siegel R,Ward E,Brawley O,et al.The impact of eliminat-ing socioeconomic and racial disparities on premature cancer deaths[J ].CA Cancer J Clin,2011,61(4):212-236.
  • 3Aune G, Stunes A K,Tingulstad S,et al.The proliferation markers Ki-67/MIB-1, phosphohistone H3,and survivin may contribute in the identification of aggressive ovarian carcinomas[J].Int J Clin Exp Pathol,2011,4(5):444-453.
  • 4Rahmanzadeh R,Rai P, Celli J P, et al.Ki-67 as a molecu- lar target for therapy in an in vitro three-dimensional model for ovarian cancer [J].Cancer Res,2010,70 (22): 9234-9242.
  • 5Kuhn E,Kurman R J,Sehdev A S,et al.Ki-67 labeling in- dex as an adjunct in the diagnosis of serous tubal intrae- pithelial carcinoma [J].Int J Gynecol Pathol,2012,31 (5): 416-422.
  • 6Li W,Cai J H,Zhang J,et al.Effects of cyclooxygenase in- hibitors in combination with taxol on expression of cyclin dl and ki-67 in a xenograft model of ovarian carcinoma[J ]. Int J Mol Sci,2012,13(8):9741-9753.
  • 7Schnipper L E,Smith T J,Raghavan D,et al.American so- ciety of clinical oncology identifies five key opportunities to improve care and reduce costs:the top five list for on- cology[J].J Clin 0ncol,2012,30(14):1715-1724.
  • 8Chalkidou A,Landau D B,Odell E W,et al.Correlation be- tween Ki-67 immunohistochemistry and 18F-fluo- rothymidine uptake in patients with cancer: A systematic review and meta-analysis [J].Eur J Cancer,2012,48(18): 3499-3513.
  • 9Keam B,Im S A,Lee K H,et al.Ki-67 can be used for fur- ther classification of triple negative breast cancer into two ~ubtypes with different response and prognosis [J].Breast Cancer Res,2011,13(2):R22.
  • 10Fasanella S,Leonardi E,Cantaloni C,et al.Proliferative ac- tivity in human breast cancer:Ki-67 automated evalua- tion and the influence of different Ki-67 equivalent an- tibodies[J].Diagn Pathol,2011,6(S 1):S7.

同被引文献13

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部